Folic acid research
This article was originally published in The Tan Sheet
Executive Summary
Low- and moderate-dose folic acid and multivitamin supplements "do not improve brachial artery flow-mediated vasodilation [FMD] in older adults with mild hyperhomocysteinemia," study published in the September American Heart Journal concludes. The prospective, single-blinded study followed 27 subjects age 70 and older with the condition for 40 weeks. Participants took placebo for 10 weeks, a daily multivitamin for 10 weeks, placebo for 10 weeks and a multivitamin supplement and folic acid supplement for 10 weeks. During the study, homocysteine levels decreased, but FMD "did not change significantly," Cynthia Carlsson, MD, University of Wisconsin, et al., conclude. FMD "did not improve after therapy with multivitamin alone," the authors add...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.